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Pacemakers are widely utilised to treat bradycardia, but right ventricular (RV) pacing is
associated with heightened risk of left ventricular (LV) systolic dysfunction and heart failure.
We aimed to compare personalised pacemaker reprogramming to avoid RV pacing with
usual care on echocardiographic and patient-orientated outcomes.
Methods
A prospective phase II randomised, double-blind, parallel-group trial in 100 patients with a
pacemaker implanted for indications other than third degree heart block for�2 years. Per-
sonalised pacemaker reprogramming was guided by a published protocol. Primary outcome
was change in LV ejection fraction on echocardiography after 6 months. Secondary out-
comes included LV remodeling, quality of life, and battery longevity.
Results
Clinical and pacemaker variables were similar between groups. The mean age (SD) of par-
ticipants was 76 (+/-9) years and 71% were male. Nine patients withdrew due to concurrent
illness, leaving 91 patients in the intention-to-treat analysis. At 6 months, personalised pro-
gramming compared to usual care, reduced RV pacing (-6.5±1.8% versus -0.21±1.7%;
p<0.01), improved LV function (LV ejection fraction +3.09% [95% confidence interval (CI)
0.48 to 5.70%; p = 0.02]) and LV dimensions (LV end systolic volume indexed to body sur-
face area -2.99mL/m2 [95% CI -5.69 to -0.29; p = 0.03]). Intervention also preserved battery
longevity by approximately 5 months (+0.38 years [95% CI 0.14 to 0.62; p<0.01)) with no
evidence of an effect on quality of life (+0.19, [95% CI -0.25 to 0.62; p = 0.402]).
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Conclusions
Personalised programming in patients with pacemakers for bradycardia can improve LV




Pacemaker implantation is a common and safe procedure that can be lifesaving and is associ-
ated with a marked improvement in quality of life [1]. Over one million people worldwide are
implanted with a pacemaker each year [2]. Cross-sectional and retrospective studies have sug-
gested that the most frequent long-term cardiovascular co-morbidity associated with right
ventricular (RV) pacemaker therapy is left ventricular systolic dysfunction (LVSD) or chronic
heart failure (CHF). Whether due to a specific pacemaker-induced cardiomyopathy or not,
CHF is associated with significant healthcare costs, [3] high morbidity and mortality, and is
much more common in pacemaker recipients than in the general population, being found in
>50% of those with a high proportion of pacemaker-induced ventricular heart beats [4].
RV pacing is associated with an immediate reduction in left ventricular (LV) function [5].
Observational studies of longer term clinical outcomes in pacemaker recipients are hampered
by the confounding of high cardiovascular co-morbidity. Nevertheless, in response to the rela-
tionship between RV pacing and LVSD and heart failure events, pacemaker manufacturers
have each developed largely automatic algorithms to avoid unnecessary RV pacing, but these
are variably applied with reprogramming occurring in only 9% of all in-clinic follow-ups [6].
We have previously described in an observational cohort that careful individualised program-
ming to limit RV pacing in people with RV pacemakers can successfully reduce pacing
requirements, and leads to an improvement in LV function with no adverse effects on quality
of life [7]. To our knowledge, no prospective randomised controlled trial has ever explored the
effects of reducing RV pacing on LV function and quality of life in patients without third
degree heart block in the era of RV pacing avoidance algorithms.
The aims of this trial were therefore to describe the effects of personalised reprogramming
to limit ventricular pacing on echocardiographic and patient-orientated clinical outcomes in
patients with avoidable RV pacing.
Methods
Data that support the findings of this study contain potentially identifying patient information.
As per the study sponsor regulations, they are therefore available upon reasonable request
(governance-ethics@leeds.ac.uk).
Trial design
This was a double-blind, randomised, controlled, parallel group, phase II study of personalised
reprogramming to avoid unnecessary RV pacing versus usual care in patients with RV pace-
makers implanted to treat bradycardia. The primary outcome of the study was change in LV
ejection fraction (LVEF) between baseline and 6 months, with secondary outcomes of LV
dimensions, quality of life (QoL), serum NT-pro-BNP concentrations and pacemaker genera-
tor longevity.
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Participants
Unselected consecutive patients attending pacemaker follow-up clinics at Leeds Teaching Hos-
pitals NHS Trust and Harrogate District Hospital NHS Foundation Trust were approached
and invited to participate. To achieve a generalisable cohort representative of patients attend-
ing a pacemaker clinic, potential participants had to have had a RV pacemaker for at least two
years, and we only included those able to provide written informed consent. We excluded peo-
ple with third degree heart block, those with cardiac resynchronization therapy devices, and a
pre-existing diagnosis of heart failure. Potential participants were offered a participant infor-
mation sheet and contacted after one week. Those agreeing to participate attended for study
visits at the NIHR Cardiovascular Clinical Research Facilities at either site and provided writ-
ten informed consent (Fig 1).
Fig 1. CONSORT participation flow diagram. Patient enrolment, randomisation, and disposition.
https://doi.org/10.1371/journal.pone.0259450.g001
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Study activities
During the baseline visit, information was collected on co-morbidities, past medical history,
medication, pacemaker settings and a QoL assessment was undertaken using EuroQoL and a
visual analogue scale of overall quality of life. A pacemaker interrogation was performed to
document implant indication, percentage atrial and ventricular pacing, and programmed
mode. We also undertook a transthoracic echocardiogram and a blood test to measure NT-
pro-B-type natriuretic peptide (NT-pro-BNP).
Echocardiographic techniques
Full two-dimensional transthoracic echocardiography was carried out with images recorded
in two- and four-chamber views (GE Vivid E95, GE Healthcare, Milwaukee, Wisconsin).
Images were stored in the EchoPAC digital imaging system (GE Healthcare) and analysed
off-line. This analysis included a calculation of LV end-diastolic volume (LVEDV), LV end-
systolic volume (LVESV) and LV ejection fraction (LVEF) using the biplane disks (modified
Simpson) method by tracing the endocardial border, excluding the papillary muscles. The
frame at the R-wave was taken as end-diastole, and the frame with the smallest LV cavity was
considered to represent end-systole. The LVEDV and LVESV indexed to body surface area
(LVEDVi and LVESVi) were calculated as LV volume/body surface area, where body surface
area was calculated using the Mosteller equation [8]. To minimize observer bias, the analysis
of cardiac ultrasound images of both studies was performed blinded to the images taken at
baseline. These were measured by two experienced reviewers and inter-observer variability
was assessed.
Intervention
Following baseline testing, patients were allocated into two groups corresponding to either
‘usual care’ or ‘personalised reprogramming’. Usual care followed the National Institute for
Health and Care Excellence (NICE) guidelines [9] and British Heart Rhythm Society standards
[10] which include advice on the activation of RV pacing avoidance algorithms. In addition to
following these guidelines, those allocated to the intervention arm underwent supplementary
reprogramming to further promote intrinsic rhythm according to our previously published
RV pacing avoidance algorithm. This included reducing day-time base rate (BR) to 50 beats
per minute(bpm), and nocturnal or sleep rate (or hysteresis where available) to 40 bpm, deacti-
vating rate-adaptive pacing, extending atrio-ventricular timing delays and reducing lead out-
puts (Fig 2).
Follow-up
Patients were contacted at one week and one month by the unblinded team member to ensure
short term acceptability and safety, and were then reviewed at six months when all tests (echo-
cardiogram, pacemaker check, quality of life assessment, and NT-pro-BNP blood test) were
repeated.
Outcomes
Our primary outcome was change in LVEF between baseline and 6 months post-randomiza-
tion. Key secondary outcomes, assessed simultaneously, included remodeling variables
(LVEDVi, LVESVi), QoL (EQ5D-3L), and remaining estimated battery longevity.
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Sample size
Our sample size was influenced by our pilot data [7]. We estimated that allocating at least 70
patients, in a 1:1 ratio to the usual care and reprogramming arms (35 in each group) would
allow us to describe a 95% confidence interval for a clinically relevant difference in mean
LVEF of 5% at 6 months post-randomization with a power of 80% [11]. Due to interest from
patients approached, recruitment was increased to 100 participants prior to study unblinding
taking place.
Randomisation and concealment. Participants were allocated to usual care or repro-
gramming using random number generation, stratified by centre. If allocated to intervention,
their device was programmed according to our previously published algorithm [7] by an
unblinded team member not involved with recruitment, data collection or analysis. The
patient and the investigator (MFP), who worked across both sites for consistency, were
blinded to allocation throughout the course of the study.
Statistical analyses
Analyses followed a predefined plan as set out in the trial protocol (NCT: 03627585). Normal-
ity for all continuous variables was tested using the Shapiro-Wilk test. Normally distributed
continuous variables were reported as mean and standard deviation (SD), and non-normally
distributed continuous variables as median and 25th-75th percentiles. Categorical variables
were presented as count and percentages. Differences between interventional groups’ baseline
characteristics were assessed using the 2-sample Student’s t-test for normally distributed data
and the Mann-Whitney U test for non-normally distributed data, whilst categorical variables
were compared using the χ2 test. Analysis of covariance (ANCOVA) was conducted to assess
inter-group significant differences for outcome variables controlling for baseline values, with
Bonferroni correction to adjust for multiplicity. All across-treatment group comparisons were
two-sided and are presented as mean change with 95% confidence intervals (95% CI). A p-
value <0.05 was deemed statistically significant for comparisons.
Fig 2. Pacemaker reprogramming protocol and its results. Simple adjustments to pacemaker programming in addition to manufacturer-specific algorithms can
reduce RV pacing, improve LV function and dimensions, lengthen battery longevity with no loss to patient quality of life.
https://doi.org/10.1371/journal.pone.0259450.g002
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Reproducibility of echocardiographic measures between two blinded echocardiographic
readers (MFP and CAC) were described by intraclass correlation coefficient (ICC). Data were
analysed using the Statistical Package for the Social Sciences SPSS version 26 (IBM Corp.,
Armonk, New York), R: A Language and Environment for Statistical Computing version 3.2.3
(R Development Core Team, Vienna, Austria), and SAS version 9.4 (SAS Institute, Inc., Cary,
North Carolina).
Patient and public involvement
The research question was driven by patients with pacemakers presenting to local HF clinics
with symptoms suggestive of CHF, a deterioration in cardiac function and a high burden of
RV pacing. The study was initially discussed with a well-established local patient and public
involvement advisory group (PPI-AG) consisting of people with cardiac devices, cardiovascu-
lar disease and their families. The PPI-AG advised on suitable follow-up periods, study proce-
dures, information sheets and dissemination plans. They were particularly interested to know
the potential effect on battery longevity of the intervention, as their primary concern was the
number of generator replacements required over a lifetime, particularly for an increasingly
frail population.
Funding and ethical considerations
Funding for the trial was through an NIHR Doctoral Fellowship award (MFP). Following ethi-
cal review by East Midlands Research Ethics Committee, the trial was approved by the Health
Research Authority of the United Kingdom (16/EM/0337) and was registered on Clinical-
Trials.gov (NCT:03627585). Full registration was retrospective due to an error in the submis-
sion process. However the authors confirm that all ongoing and related trials for this drug/
intervention are registered.
Results
A total of 100 patients were recruited from two centres between January 2017 and September
2018. Of the 100 patients, 9 withdrew due to serious illness, all of which were non-cardiovascu-
lar. No patients reported changes to their medical therapy during the study period. No patient
randomised to intervention reported adverse effects from device reprogramming (Fig 1).
Patient and clinical characteristics were similar between intervention groups for age, sex,
baseline RV pacing burden, LVEF, NT-proBNP and pacemaker battery longevity (Table 1).
More than half (71%) were male with a mean age of 76 (SD±9) years. Co-morbidities included
diabetes mellitus (31%), history of myocardial infarction (13%), percutaneous coronary inter-
vention (10%), previous coronary artery bypass grafting (8%). Patients had a median atrial
pacing burden of 27 (3–67)% and RV pacing percentage of 9 (1–58)% with a mean resting
heart rate of 69 (±12)bpm. Mean LVEF was 50 (±9), with no evidence of a difference in those
with a baseline LVEF�50% (preserved LVEF) and without (reduced LVEF) between interven-
tional groups (27 randomised to personalised programming vs 32 to usual care; p = 0.31), and
median NT-proBNP was 1423 (±3783)pg/mL.
Distribution of device manufacturers is shown in (S1 Table). There were no significant dif-
ferences in pacemaker lead site or type between the groups. All patients were paced at the right
ventricular apex. Approximately half of the participants had a passive atrial lead (52% in the
usual care group vs 50% randomised to personalised programming; p = 0.50), and 82% had a
passive ventricular lead (82% in the usual care group vs 83% randomised to personalised pro-
gramming; p = 0.54).
PLOS ONE Pacemaker programming prevents remodeling
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Table 1. Patient characteristics at baseline.
Total Interventional Group p-value
Personalised Programming Usual Care
(n = 100) (n = 50) (n = 50)
Patient Demographics
Age (years) 76 (9) 75 (10) 76 (9) 0.579
Sex (male) 71 (71) 35 (70) 36 (72) 0.368
Height (cm) 169 (15) 170 (10) 167 (19) 0.376
Weight (kg) 82 (19) 84 (19) 80 (20)
Atrial Rhythm
Atrial Fibrillation 39 (39) 22 (44) 17 (34) 0.450
Paced 3 (3) 2 (4) 1 (2)
Sinus Rhythm 58 (58) 26 (52) 32 (64)
Clinical History Data
Myocardial Infarction 13 (13) 6 (12) 7 (14) 0.766
Diabetes Mellitus 31 (31) 20 (40) 11 (22) 0.052
CABG 8 (8) 3 (6) 5 (10) 0.461
PCI 10 (10) 4 (8) 6 (12) 0.505
CVA 18 (18) 9 (18) 9 (18%) 0.962
NYHA
I 48 (48) 27 (54) 21 (42) 0.230
II 52 (52) 23 (46) 29 (58)
Haemodynamic Data
Resting Heart Rate (bpm) 69 (12) 69 (12) 69 (12) 0.150
Resting Systolic BP(mmHg) 138 (23) 138 (22) 138 (24) 0.158
NT-pro-BNP (pg/ml) 1423 (3783) 1368 (3028) 1473 (4396) 0.894
Pacing Data
Pacing indication
Atrioventricular block 30 (30) 15 (30) 15 (30) 0.602
Sinus Node Disease 69 (69) 34 (68) 35 (70)
Other 1 (1) 1 (2) 0 (0)
Dual chamber pacemaker 91(91) 45(90) 46(92) 0.500
Time since first pacemaker (years) 11 (7) 12 (8) 11 (5) 0.317
Atrial pacing proportion (%) 27 (3–67) 25 (4–69) 31 (3–68) 0.796
Ventricular pacing proportion (%) 10 (1–58) 9 (1–73) 11 (2–42) 0.841
Echocardiographic Data
LVEF (%) 50 (9) 49 (10) 50 (9) 0.732
Preserved EF (>/= 50%) 59 (59) 27 (54) 32 (64) 0.310
LVEDV (mL) 107 (78–122) 106 (66–122) 107 (77–124) 0.802
LVESV (mL) 47 (37–60) 47 (37–60) 44 (37–60) 0.924
LVESVi (mL/m2) 24 (15–31) 24 (20–31) 23 (20–33) 0.710
LV diastolic dysfunction grade
Normal 20 (20) 47 (14) 13 (26) 0.368
I 50 (50) 27 (54) 23 (46)
II 29 (29) 15 (30) 14 (28)
III 1 (1) 1 (1) 0 (0)
Medical Therapy Data
Beta-blocker 45 (45) 19 (38) 26 (52) 0.159
ACEi/ARB 47 (47) 23 (46) 24 (48) 0.841
(Continued)
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Patients were followed for a median of 189 days (interquartile range 176, 230), similar
between intervention groups. No patient developed third degree AV block and no patient
experienced an acute coronary syndrome or new or worsening heart failure event requiring
hospitalisation or urgent ambulatory visit during follow-up. At baseline, most patients were
programmed in DDD or VVI mode with rate response active in 40%, and an average base rate
of 54(±6)bpm (S2 Table). Despite usual care already including pacing avoidance algorithms,
supplementary personalised pacemaker programming successfully achieved an additional
reduction in RV pacing percentage compared with usual care (-7% [95% confidence interval
-11 to -2%; p = 0.01]). This was achieved by a reduction in base rate (in 44%), reductions in
sleep, rest or hysteresis rates (68%), altered mode (8%), deactivating rate-adaptive pacing
mode(38%), activating atrioventricular search algorithms (4%), activating automatic threshold
algorithms (36%), reducing lead outputs (74%) and deactivating electrocardiogram storage
where not necessary (10%). These proportions were similar across manufacturers. During the
follow-up period, there were no changes to guideline directed standard of care programming
in those allocated usual care. Changes in the pacemaker programming at follow-up between
the groups are outlined in (S2 Table). There was no evidence of a statistical or clinically signifi-
cant difference in incidence of atrial fibrillation during the 6 month follow-up in patients ran-
domised to personalised programming compared to usual care (-3±16% vs. -2±16%; p = 0.66).
Primary outcome measure
There was an improvement in the primary endpoint of LV systolic function, measured by
LVEF, at 6 months in patients randomised to receive personalised pacemaker programming
when compared with those receiving usual care (mean difference (+3.09% [0.48 to 5.70%;
p = 0.02]) (Fig 3 and Table 2).
Secondary outcome measures
There was a reduction in mean LVEDVi of -2.88mL/m2 (95% CI -7.83 to 2.07; p = 0.249) mL/
m2 in those allocated to personalised care, compared to those receiving usual care, when cor-
rected for baseline LVEDVi, although our sample did not provide sufficient statistical evidence
to conclude this effect exists. Moreover, patients randomised to personalised programming
had a significantly smaller LVESVi at follow-up than those randomised to usual care
(-2.99mL/m2 [95% CI -5.69 to -0.29 mL/m2; p = 0.03]) (Fig 3 and Table 2). Of those allocated
personalised programming, 8 (30%) experienced a clinically significant reduction in LVESVi
by greater than 15% compared to 2 (7%) patients randomised to usual care (p = 0.02). We did
not see a difference in atrial fibrillation burden during follow-up.
Personalising pacemaker settings to avoid unnecessary RV pacing had no detrimental
effect on quality of life as measured by EQ5D-3L (+0.19 [95% CI -0.25 to 0.62; p = 0.402]) and
Table 1. (Continued)
Total Interventional Group p-value
Personalised Programming Usual Care
(n = 100) (n = 50) (n = 50)
Furosemide 21 (21) 10 (20) 11 (22) 0.806
Continuous normally distributed data are expressed as mean (SD), non-normally distributed continuous data as median (IQR) or categorical data as n (%).
CABG; coronary artery bypass grafting, PCI; percutaneous coronary intervention, CVA; cerebrovascular attack, BP; blood pressure, LVEF; left ventricular ejection
fraction, LVEDV; left ventricular end diastolic volume, LVESV; left ventricular end-systolic volume, LVESVi; left ventricular end-systolic volume index, ACEi;
Angiotensin-converting-enzyme inhibitor, ARB; Angiotensin II receptor blocker.
https://doi.org/10.1371/journal.pone.0259450.t001
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visual analogue scale (VAS) (-0.03 [-7.60 to 7.54; p = 0.99]) when adjusted for baseline quality
of life.
Furthermore, personalised programming led to an extension of remaining minimum bat-
tery longevity by approximately 5 months compared with usual care (+0.38 years [0.14 to 0.62
years; p<0.01]) (Fig 3 and Table 2).
Subgroup analysis
An exploratory subgroup analysis showed in those with a preserved LVEF at baseline, LVEF
improved by a mean of +4% (95%CI 0.94 to 7.57; p = 0.01) with personalised programming. In
Fig 3. Primary and secondary outcomes by allocation. Mean change and standard deviation in LV diastolic and systolic
volume index, left ventricular ejection fraction and minimum device longevity following 6 months of usual care
programming versus personalised programming.
https://doi.org/10.1371/journal.pone.0259450.g003
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participants with a reduced LVEF (<50%) at baseline, there was a non-significant mean
increase in LVEF of 2% (95%CI -2.03 to +6.71%; p = 0.29) in those allocated personalised
programming.”
Analysis of the primary outcome in the first 70 recruited patients shows an improvement
in LVEF with personalised programming which did not meet statistical significance (+2.52%
[95%CI -0.44 to 5.49%; p = 0.09]) (S3 Table).
Reproducibility of echocardiographic measurements
Echocardiographic outcome measurements demonstrated strong inter-observer agreement for
LVEF [ICC 0.968 (0.948 to 0.980)], LVEDV [ICC 0.955 (0.931 to 0.975)], and LVESV (ICC
0.964 (0.941 to 0.979)].
Discussion
The present study is the first to provide evidence that even when right ventricular pacing bur-
den is already low, and pacing avoidance algorithms are already activated, personalising pace-
maker programming to limit RV pacing even further leads to a clinically relevant improvement
in LV systolic function and prevents further remodeling, with no evidence of an effect on qual-
ity of life, whilst simultaneously preserving battery longevity.
Table 2. Change in primary and secondary outcome variables in patients following 6 months of personalised pacemaker programming v usual care: Intention-to-
treat analysis.
Outcome Randomised treatment Mean at follow-up [95% Confidence Interval] Mean difference [95% Confidence Interval P value
Primary outcome
LVEF (%) Reprogramming 51.05 [49.15, 52.94] +3.09 [0.48, 5.70] 0.02�
Usual care 47.96 [46.16, 49.75]
Secondary outcomes
LVEDV (mL) Reprogramming 104.30 [96.99, 111.61] -4.81 [-14.72, 5.11] 0.34
Usual care 109.10 [102.41, 115.80]
LVESV (mL) Reprogramming 52.99 [49.20, 56.78] -5.08 [-10.26, 0.11] 0.06
Usual care 58.07 [54.44, 61.60]
LVEDVi (mL/ m2) Reprogramming 53.33 [49.72, 56.97] -2.88 [-7.83, 2.07] 0.25
Usual care 56.22 [52.85, 59.59]
LVESVi (mL/m2) Reprogramming 26.95 [24.99, 28.90] -2.99 [-5.69, -0.29] 0.03�
Usual care 29.93 [28.08, 31.79]
NT-proBNP (pg/mL) Reprogramming 1136.22 [768.02, 1504.43] -87.83 [-450.95, 626.61] 0.75
Usual care 1224.05 [831.08, 1617.02]
Battery Longevity (years) Reprogramming 6.15 [5.98, 6.32] +0.38 [0.14, 0.62] <0.01�
Usual care 5.77 [5.60, 5.93]
EQ5D Reprogramming 0.69 [0.38, 1.02] +0.19 [-0.25, 0.62] 0.40
Usual care 0.51 [0.22, 0.81
EQ-VAS Reprogramming 74.44 [68.97, 79.90] -0.03 [-7.60, 7.54] 0.99
Usual care 74.47 [69.25, 79.69]
Values are mean change [95% confidence intervals]; 95% significance shown in bold,
�Denotes significance (P<0.05).
LVEF; left ventricular ejection fraction, LVEDV; left ventricular end-diastolic volume, LVESV; left ventricular end systolic volume, LVESVi; left ventricular end systolic
volume index, NT-proBNP; N-terminal pro-B-type natriuretic peptide, EQ5D; Euro-quality of life score -5 questions, VAS; visual analogue scale.
https://doi.org/10.1371/journal.pone.0259450.t002
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RV pacing-associated LV dysfunction
RV pacing has a longstanding association with an acute reduction in LV contractility. In two
separate cross-sectional studies of unselected patients with pacemakers, we have described and
validated that the degree of LV dysfunction is strongly related to the amount of RV pacing,
and that this relationship is enhanced by the presence of cardiovascular disease [5, 6]. Hence,
most patients with LV dysfunction attending a pacemaker clinic will not fulfill the exacting cri-
teria of pacemaker-induced cardiomyopathy [4]. rather the RV pacing will be a contributor.
Longer term effects on LV function are reported to include myocardial perfusion and struc-
tural abnormalities [12]. thought eventually to contribute to the initiation and progression
of LV adverse remodeling with the subsequent progression to LVSD and CHF. However,
whether this LV dysfunction is progressive, and the underlying mechanisms behind the het-
erogeneity in functional response to RV pacing are both currently unknown.
LV remodeling in RV pacemaker patients
Reverse remodeling is increasingly appreciated as a surrogate for improved patient-orientated
outcomes, due to a close relationship between therapy-related changes in echocardiographic
variables (in HF patients) and subsequent findings in morbidity and mortality studies of the
same interventions. A pooled analysis of interventional clinical trial data has shown that every
5% absolute increase in mean LVEF is associated with an odds ratio of 0.86 (95% CI 0.77 to
0.96) for mortality [13]. Similar data apply to LV volumes. A reduction in LVESVi of�15% is
associated with better outcomes in recipients of cardiac resynchronisation therapy (CRT), [14]
and has been used as an endpoint in CRT studies previously. Our data suggest therefore, that a
long-term application of personalised pacemaker therapy could improve outcomes.
Does RV pacing-associated LV impairment affect outcomes?
Observational data in pacemaker recipients without clinical heart failure at baseline has also
shown higher heart failure-associated deaths and hospitalisation rates as RV pacing burden
increases, the risk of which is highest within the first 6 months post-pacemaker implantation
[15, 16]. Although these studies could not prove causation, the most consistent feature predict-
ing mortality in each of these studies was cardiac dysfunction at baseline and a high RV pacing
proportion.
Can RV pacing be avoided?
In experimental models, reducing RV pacing seems to correct pacing-induced left ventricular
systolic dysfunction. We previously undertook an observational study in 66 patients with long
term pacemakers to determine whether reducing RV pacing in a chronically implanted patient
cohort had effects upon LV function [7]. On an intention-to-treat analysis, the protocol
reduced mean RV pacing percentage by 49% (95% CI 41 to 57%; p<0.0001) from baseline,
and there was an improvement in LVEF of 6% (95% CI 4 to 8%; p<0.0001) and a reduction in
LV dimensions.
Since our initial work, manufacturers’ bespoke RV pacing avoidance algorithms have
become standard of care, hence the present study was carried out on a background of low RV
pacing burden in patients not necessarily fulfilling the precise diagnosis of pacemaker-induced
cardiomyopathy. The impact of RV pacing on cardiac function is likely to be variable in the
context of contributing factors such as co-morbidities, but there may be a dose-response rela-
tionship over a lifetime of pacemaker therapy. This study is the first to confirm that simple
pacing adjustments are well tolerated and also that even a modest further reduction in RV
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pacing burden is associated with improvements in LV size and function, hence, any attempt to
reduce pacing burden is a worthwhile endeavor.
Exploratory subgroup analysis also showed that personalising pacemaker programming is
as important to those with a preserved LVEF. Patients with preserved LVEF at baseline experi-
enced a larger absolute increase in LVEF. One could hypothesise that potentially the earlier in
the patients disease status we implement personalised programming, the more likely we are to
preserve LV size and function, but certainly personalised programming seems to be beneficial
in all patients. As the present study is a phase II study, a larger investigation with greater
power is required to extend these findings into clinical endpoints of relevance to patients.”
The opportunity to improve device longevity
Whilst avoiding RV pacing and improving or maintaining LV function is likely to be benefi-
cial, device longevity is the most important aspect of pacemaker therapy to patients and has
featured in the medical and the lay press [17]. The amount of pacing the device has to perform
is the major drain on battery current and studies have previously suggested reprogramming
can have beneficial effects on predicted pacemaker longevities [18] and therefore potentially
reduce the complication rate of patient undergoing generator replacement procedures.
The results of this study therefore provide the first data from a randomised, placebo-
controlled trial of chronically implanted pacemakers, that even many years following
implant, and despite widespread use and promotion of RV pacing avoidance technology by
companies and guidelines, careful programming using our algorithm further reduced RV
pacing and had other positive effects, such as a preservation of battery longevity. Address-
ing programming earlier in the life of a pacemaker battery is likely to have cumulative
effects upon device longevity.
Safety and patient tolerability
Our protocol, which included a lowering of the base rate and deactivating rate-adaptive pac-
ing, was well-tolerated with no patients returning with or reporting symptoms and no detri-
ment to their quality of life. This finding is consistent with previous data where rate-adaptive
pacing has been associated with highly variable effects on measures of quality of life [19].
International and national guidelines
Currently international guidelines state that RV pacing should be avoided if possible, [9, 10,
20] but they offer limited advice on how this should be done. Clinical practice often relies on
local policy and how pacemakers are programmed is highly variable. The present data describe
benefits on clinical outcomes and battery longevity which, if included in guidelines, have the
potential to not only reduce clinical event rates but also improve generator longevity—both
key drivers of cost effectiveness.
Limitations
Although this trial was performed within two centres, they reside within a single region in the
UK, potentially limiting generalisability, particularly as international pacemaker programming
may differ. However, baseline demographic data indicate that our population was representa-
tive of a pacemaker recipient population.
We did not limit enrolment only to patients with a pacing-induced cardiomyopathy,
defined by a specific reduction in LVEF from pre-implant levels due to the presence of the
pacemaker [3, 4]. We chose instead to enroll unselected patients attending a routine
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pacemaker clinic, with a view to exploring the benefits across the population in whom the
pacemaker is likely to be contributing, rather than the primary cause of LV dysfunction. Our
data suggest that even in the absence of a proven pacemaker-induced cardiomyopathy, opti-
mised programming should be undertaken.
Estimated battery longevity remaining, rather than actual battery longevity, was utilised as a
pragmatic measure of longevity due to the variable data available at follow-up between manu-
facturers. Whilst energy consumption or battery voltage may have provided additional infor-
mation, this was not routinely obtainable from all devices included in the study, nor is it
routinely available clinically.
Although the present study demonstrated modest benefits on LV function and battery lon-
gevity from personalised programming, these are likely to be cumulative, especially if initiated
early following implantation. Longer term follow-up in a larger multi-centre trial including
patients with a greater severity of sinus node disease would allow for further sub-analysis to
understand which programming modifications show the greatest effect.
Conclusions
Personalised reprogramming to avoid unnecessary RV pacing in unselected patients with RV
pacemakers, beyond manufacturers’ pacing avoidance algorithms, can improve LV function,
extend battery longevity, and is safe and acceptable to patients.
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